This company has been marked as potentially delisted and may not be actively trading. NASDAQ:HUGE FSD Pharma (HUGE) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About FSD Pharma Stock (NASDAQ:HUGE) 30 days 90 days 365 days Advanced Chart Get FSD Pharma alerts:Sign Up Key Stats Today's Range$0.23▼$0.2350-Day Range$0.08▼$0.2052-Week Range$0.07▼$1.68VolumeN/AAverage Volume10.14 million shsMarket Capitalization$9.11 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewFSD Pharma Inc., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. FSD Pharma Inc. is headquartered in Toronto, Canada.Read More… Receive HUGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for FSD Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address HUGE Stock News HeadlinesWall Street bets that Musk will take advantage of Trump and already values Tesla at three times the combined value of the top ten European manufacturersNovember 14, 2024 | msn.comWhat the NFL Draft Can Teach Investors About Big PharmaNovember 12, 2024 | wsj.comHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First policies, a historic wave of investment is flooding back into the United States: Apple committing a colossal $500 billion to build new U.S. factories. Microsoft injecting $80 billion into domestic manufacturing. Nvidia moving critical chip production back to America. But here's the hidden opportunity: There's now a groundbreaking way for you to start collecting monthly checks from these very same companies— checks that could reach as high as $5,917 each month. Don't miss your chance to participate directly in America's industrial comeback.July 1 at 2:00 AM | Investors Alley (Ad)Tesla extends post-election rally after Wedbush boosts its price targetNovember 11, 2024 | seekingalpha.comZealand Pharma Gains as JPMorgan Flags $10 Billion OpportunityNovember 8, 2024 | bloomberg.comBig Pharma’s Obesity Bonanza Faces New TestsNovember 4, 2024 | msn.comWhy Elon Musk’s Robotaxi Dreams Are PrematureNovember 2, 2024 | finance.yahoo.comTesla: Profitability Increases Should Drive Stock HigherOctober 24, 2024 | seekingalpha.comSee More Headlines HUGE Stock Analysis - Frequently Asked Questions How were FSD Pharma's earnings last quarter? FSD Pharma Inc. (NASDAQ:HUGE) released its earnings results on Tuesday, November, 14th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.11. What other stocks do shareholders of FSD Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that FSD Pharma investors own include Meta Platforms (META), SNDL (SNDL), AMC Entertainment (AMC), Ford Motor (F), NVIDIA (NVDA), Fiverr International (FVRR) and NIO (NIO). Company Calendar Last Earnings11/14/2023Today6/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolNASDAQ:HUGE CIK1771885 Webfsdpharma.com Phone(416) 854-8884FaxN/AEmployees17Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$17.90 million Net MarginsN/A Pretax MarginN/A Return on Equity-74.06% Return on Assets-55.31% Debt Debt-to-Equity RatioN/A Current Ratio2.34 Quick Ratio2.34 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.33 per share Price / Book0.69Miscellaneous Outstanding Shares40,117,000Free Float36,695,000Market Cap$9.11 million OptionableOptionable Beta0.60 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:HUGE) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredGold prediction: $5,000/oz. or higher is comingThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FSD Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share FSD Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.